JP2014513712A5 - - Google Patents

Download PDF

Info

Publication number
JP2014513712A5
JP2014513712A5 JP2014510872A JP2014510872A JP2014513712A5 JP 2014513712 A5 JP2014513712 A5 JP 2014513712A5 JP 2014510872 A JP2014510872 A JP 2014510872A JP 2014510872 A JP2014510872 A JP 2014510872A JP 2014513712 A5 JP2014513712 A5 JP 2014513712A5
Authority
JP
Japan
Prior art keywords
asenapine maleate
monoclinic
stable
less
finely divided
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014510872A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014513712A (ja
JP6014656B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2012/000450 external-priority patent/WO2012156677A1/en
Publication of JP2014513712A publication Critical patent/JP2014513712A/ja
Publication of JP2014513712A5 publication Critical patent/JP2014513712A5/ja
Application granted granted Critical
Publication of JP6014656B2 publication Critical patent/JP6014656B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014510872A 2011-05-18 2012-05-18 化合物の多形体 Active JP6014656B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161487495P 2011-05-18 2011-05-18
US61/487,495 2011-05-18
PCT/GB2012/000450 WO2012156677A1 (en) 2011-05-18 2012-05-18 A stable micronised monoclinic form of asenapine maleate and its synthesis

Publications (3)

Publication Number Publication Date
JP2014513712A JP2014513712A (ja) 2014-06-05
JP2014513712A5 true JP2014513712A5 (enExample) 2015-07-02
JP6014656B2 JP6014656B2 (ja) 2016-10-25

Family

ID=46168537

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014510872A Active JP6014656B2 (ja) 2011-05-18 2012-05-18 化合物の多形体

Country Status (5)

Country Link
US (1) US9505771B2 (enExample)
EP (1) EP2709616B1 (enExample)
JP (1) JP6014656B2 (enExample)
ES (1) ES2665843T3 (enExample)
WO (1) WO2012156677A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2802990A1 (en) * 2010-06-18 2011-12-22 Dr. Reddy's Laboratories Ltd. Asenapine maleate
US10085971B2 (en) 2016-08-22 2018-10-02 Navinta Iii Inc Pharmaceutical solution of asenapine for sublingual or buccal use
CA3047451A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CA3047354A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
CN110799180A (zh) 2017-06-26 2020-02-14 罗曼治疗系统股份公司 含阿塞那平和硅氧烷丙烯酸杂化聚合物的经皮治疗系统
BR112020026099A2 (pt) 2018-06-20 2021-03-23 Lts Lohmann Therapie-Systeme Ag sistema terapêutico transdérmico que contém asenapina
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US20250032451A1 (en) * 2021-11-24 2025-01-30 Oakwood Laboratories, Llc Microsphere formulations comprising asenapine and methods for making and using the same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7605526A (nl) 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
KR100330942B1 (ko) * 1994-03-02 2002-11-16 악조 노벨 엔.브이. 설하또는협측투여용약학조성물
CA2431890C (en) * 2000-12-27 2011-05-10 Ares Trading S.A. Lipid microparticles by cryogenic micronization
RU2405786C2 (ru) * 2005-04-07 2010-12-10 Н.В. Органон Кристаллическая форма малеата азенапина
US7872147B2 (en) 2005-04-07 2011-01-18 N. V. Organon Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
US7741358B2 (en) * 2005-04-14 2010-06-22 N.V. Organon Crystal form of asenapine maleate
US7750167B2 (en) 2006-07-05 2010-07-06 N.V. Organon Process for the preparation of asenapine and intermediate products used in said process
WO2008148515A1 (en) * 2007-06-05 2008-12-11 Synthon B.V. Intranasal administration of asenapine and pharmaceutical compositions therefor
CA2802990A1 (en) 2010-06-18 2011-12-22 Dr. Reddy's Laboratories Ltd. Asenapine maleate
US8653280B2 (en) * 2010-07-29 2014-02-18 Laboratories Lesvi, S.L. Process for the preparation of asenapine
WO2012038975A2 (en) 2010-09-22 2012-03-29 Msn Laboratories Limited Process for the preparation of (3ars,12brs)-5-chloro-2-methyl-2,3,3a12b-tetrahydro-1hdibenzo[2,3:6,7] oxepino [4,5-c]pyrrole maleate and it's pharmaceutical composition thereof
WO2012066565A2 (en) 2010-11-16 2012-05-24 Cadila Healthcare Limited Asenapine maleate amorphous and crystalline form and process for preparation thereof
EP2468750A1 (en) * 2010-12-13 2012-06-27 Chemo Ibérica, S.A. Polymorphic forms of asenapine maleate and processes for their preparation
ITMI20110734A1 (it) * 2011-05-02 2012-11-03 Olon Spa Sali cristallini di asenapina
US9533994B2 (en) * 2011-05-18 2017-01-03 Laboratorios Lesvi S.L. Monoclinic crystalline form of asenapine maleate with a specific particle size distribution

Similar Documents

Publication Publication Date Title
JP2014513712A5 (enExample)
JP2013237682A5 (enExample)
WO2013132457A3 (en) Nanocrystalline solid dispersion compositions and process of preparation thereof
AR122183A2 (es) Proceso para la preparación de una forma cristalina de un inhibidor de pde4, forma cristalina, composición farmacéutica para inhalación, usos y solvato
NZ616637A (en) Preparation of high-purity gadobutrol
TN2014000356A1 (en) Heterocyclyl compounds as mek inhibitors
IN2014DN09352A (enExample)
MX2013008056A (es) 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
JP2013543867A5 (enExample)
RU2015128794A (ru) Композиция перорально распадающейся таблетки, обеспечивающая повышенную биодоступность
GEP20166483B (en) Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament
JP2011522827A5 (enExample)
WO2010018112A3 (en) Monoaryl aminotetralines
JP2015500331A5 (enExample)
ES2606307T3 (es) Producto de co-micronización que comprende acetato de ulipristal
JP2017519015A5 (enExample)
JP2015522037A5 (enExample)
CA2920410C (en) Thienopiperidine derivative and use thereof
IN2014DN09347A (enExample)
JP2015516425A5 (enExample)
NZ601920A (en) New crystalline form of a cyclopropyl benzamide derivative
CN104829603A (zh) A晶型依匹唑派盐酸盐及其制备方法
PH12013500545A1 (en) Oxadiazole inhibitors of leukotriene production
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
JP2010540440A5 (enExample)